Suppr超能文献

[HOXC10基因对胶质瘤细胞生物学行为的影响及其在肿瘤微环境中的机制]

[The effect of HOXC10 gene on biological behaviors of glioma cells and mechanism in tumor microenvironment].

作者信息

Jiang W Y, Lei Q Y, Liu S S, Yang L, Yang B, Zhang Y

机构信息

Biotherapy Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

Department of Neurosurgery, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

出版信息

Zhonghua Zhong Liu Za Zhi. 2022 Mar 23;44(3):228-237. doi: 10.3760/cma.j.cn112152-20200326-00266.

Abstract

To study the effects of Homeobox C10 (HOXC10) on biological characteristics such as migration, invasion and proliferation of glioma cancer cells and to explore the role of HOXC10 gene in glioma microenvironment. The expression level of HOXC10 in high grade glioma (glioblastoma) and low grade glioma and its effect on patient survival were analyzed by using The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) database. Hoxc10-siRNA-1, HOXC10-siRNA-2 and siRNA negative control (NC) were transfected into U251 cells according to the operation instructions of HOXC10-siRNA transfection. 100 ng/ mL recombinant protein chemokine ligand 2 (reCCL2) was added into the transfection group, and was labeled as HOXC10-siRNA-1+ reCCL2 and HOXC10-siRNA-2+ reCCL2 groups. The expressions of HOXC10 mRNA and target protein in each group was detected by real-time fluorescence quantitative polymerase chain reaction (qRT-PCR) and western blot. The proliferation ability of cells in each group was detected by cell counting kit 8 (CCK8) method. The migration ability of cells was detected by Transwell assay and Nick assay, and cell apoptosis was detected by flow cytometry. The expression of chemokines in each group was detected by multiple factors. Co-incubation assays were performed to determine the role of HOXC10 and chemokine ligand 2 (CCL2) in recruiting and polarizing tumor-associated macrophages (M2-type macrophages). The median expression level of HOXC10 in high grade gliomas was 8.51, higher than 1.00 in low grade gliomas (<0.001) in TCGA database. The median expression level of HOXC10 in high grade gliomas was 0.83, higher than 0.00 in low grade gliomas (=0.002) in CGGA database. The 5-year survival rate of patients with high HOXC10 expression in TCGA database was 28.2%, lower than 78.7% of those with low HOXC10 expression (<0.001), and the 5-year survival rate of patients with high HOXC10 expression in CGGA database was 20.3%, lower than 58.0% of those with low HOXC10 expression (<0.001). The numbers of cell migration in HOXC10-siRNA-1 group and HOXC10-siRNA-2 group were (45±3) and (69±4) respectively, lower than (159±3) in NC group (<0.05). The cell mobility of HOXC10-siRNA-1 group and HOXC10-siRNA-2 group at 48 hours were (15±2)% and (28±4)% respectively, lower than (80±5)% of NC group (<0.05). The expressions of vimentin in HOXC10-siRNA-1 group and HOXC10-siRNA-2 group were (141 740.00±34 024.56) and (94 655.00±5 687.97), N-cadherin were (76 810.00±14.14) and (94 254.00±701.45), β-catenin were (75 786.50±789.84) and (107 296.50±9 614.53), lower than (233 768.50±34 114.37), (237 154.50±24 715.50) and (192 449.50±24 178.10) of NC group (<0.05). The value of HOXC10-siRNA-1 group and HOXC10-siRNA-2 group were (0.44±0.05) and (0.32±0.02) at 96 hours, lower than 0.92±0.12 of NC group (<0.05). The apoptosis rates of HOXC10-siRNA-1 group and HOXC10 siRNA-2 group were (10.23±1.24)% and (13.81±2.16)%, higher than (4.60±0.07)% of NC group (<0.05). The expression levels of CCL2 in U251 cells in HOXC10-siRNA-1 and HOXC10-siRNA-2 groups were (271.63±44.27) and (371.66±50.21), lower than (933.93±29.84) in NC group (<0.05). The expression levels of CCL5 (234.81±5.95 and 232.62±5.72), CXCL10 (544.13±48.14 and 500.87±15.65) and CXCL11 (215.75±15.30 and 176.18±16.49) in HOXC10-siRNA-1 and HOXC10-siRNA-2 groups were higher than those in NC group (9.98±0.71, 470.54±18.84 and 13.55±0.73, respectively, <0.05). The recruited numbers of CD14(+) THP1 in HOXC10-siRNA-1 and HOXC10-siRNA-2 groups were (159.33±1.15) and (170.67±1.15), respectively, lower than (360.00±7.81) in NC group (<0.05), while addition of reCCL2 promoted the recruitment of CD14(+) THP1 cells (287.00±3.61 and 280.67±2.31 in HOXC10-siRNA-1+ reCCL2 group and HOXC10-siRNA-2+ reCCL2 group, respectively, <0.05). The expressions level of M2-type macrophage-related gene TGF-β in HOXC10-siRNA-1 group and HOXC10-siRNA-2 group were (0.30±0.02) and (0.28±0.02), respectively, lower than (1.06±0.10) in NC group (<0.05). The expressions level of M1-related gene NOS2 in HOXC10-siRNA-1 and HOXC10-siRNA-2 were (11 413.95±1 911.85) and (5 894.00±945.21), respectively, higher than (13.39±4.32) in NC group (<0.05). The expression of HOXC10 in glioma is high and positively correlated with the poor prognosis of glioma patients. Knockdown of HOXC10 can inhibit the proliferation, migration and metastasis of human glioma U251 cells. HOXC10 may play an immunosuppressive role in glioma microenvironment by promoting the expression of CCL2 and recruiting and polarizing tumor-associated macrophages (M2 macrophages).

摘要

研究同源框C10(HOXC10)对胶质瘤癌细胞迁移、侵袭和增殖等生物学特性的影响,并探讨HOXC10基因在胶质瘤微环境中的作用。利用癌症基因组图谱(TCGA)和中国胶质瘤基因组图谱(CGGA)数据库分析HOXC10在高级别胶质瘤(胶质母细胞瘤)和低级别胶质瘤中的表达水平及其对患者生存的影响。按照HOXC10-siRNA转染操作说明,将Hoxc10-siRNA-1、HOXC10-siRNA-2和siRNA阴性对照(NC)转染至U251细胞。转染组加入100 ng/mL重组蛋白趋化因子配体2(reCCL2),分别标记为HOXC10-siRNA-1+reCCL2组和HOXC10-siRNA-2+reCCL2组。采用实时荧光定量聚合酶链反应(qRT-PCR)和蛋白质免疫印迹法检测各组HOXC10 mRNA和靶蛋白的表达。采用细胞计数试剂盒8(CCK8)法检测各组细胞的增殖能力。采用Transwell实验和划痕实验检测细胞的迁移能力,采用流式细胞术检测细胞凋亡情况。采用多因子检测各组趋化因子的表达。通过共孵育实验确定HOXC10和趋化因子配体2(CCL2)在募集和极化肿瘤相关巨噬细胞(M2型巨噬细胞)中的作用。在TCGA数据库中,高级别胶质瘤中HOXC10的中位表达水平为8.51,高于低级别胶质瘤中的1.00(<0.001)。在CGGA数据库中,高级别胶质瘤中HOXC10的中位表达水平为0.83,高于低级别胶质瘤中的0.00(=0.002)。在TCGA数据库中,HOXC10高表达患者的5年生存率为28.2%,低于HOXC10低表达患者的78.7%(<0.001);在CGGA数据库中,HOXC10高表达患者的5年生存率为20.3%,低于HOXC10低表达患者的58.0%(<0.001)。HOXC10-siRNA-1组和HOXC10-siRNA-2组的细胞迁移数分别为(45±3)和(69±4),低于NC组的(159±3)(<0.05)。HOXC10-siRNA-1组和HOXC10-siRNA-2组在48小时时的细胞迁移率分别为(15±2)%和(28±4)%,低于NC组的(80±5)%(<0.05)。HOXC10-siRNA-1组和HOXC10-siRNA-2组波形蛋白的表达分别为(141 740.00±34 024.56)和(94 655.00±5 687.97),N-钙黏蛋白分别为(76 810.00±14.14)和(94 254.00±701.45),β-连环蛋白分别为(75 786.50±789.84)和(107 296.50±9 614.53),低于NC组的(233 768.50±34 114.37)、(237 154.50±24 715.50)和(192 449.50±24 178.10)(<0.05)。HOXC10-siRNA-1组和HOXC10-siRNA-2组在96小时时的吸光度值分别为(0.44±0.05)和(0.32±0.02),低于NC组的0.92±0.12(<0.05)。HOXC10-siRNA-1组和HOXC10-siRNA-2组的凋亡率分别为(10.23±1.24)%和(13.81±2.16)%,高于NC组的(4.60±0.07)%(<0.05)。HOXC10-siRNA-1组和HOXC10-siRNA-2组U251细胞中CCL2的表达水平分别为(271.63±44.27)和(371.66±50.21),低于NC组的(933.93±29.84)(<0.05)。HOXC10-siRNA-1组和HOXC10-siRNA-2组中CCL5(234.81±5.95和232.62±5.72)、CXCL10(544.13±48.14和500.87±15.65)和CXCL11(215.75±15.30和176.18±16.49)的表达高于NC组(分别为9.98±0.71、470.54±18.84和13.55±0.73,<0.05)。HOXC10-siRNA-1组和HOXC10-siRNA-2组中CD14(+)THP1的募集数分别为(159.33±1.15)和(170.67±1.15),低于NC组的(360.00±7.81)(<0.05),而加入reCCL2可促进CD14(+)THP1细胞的募集(HOXC10-siRNA-1+reCCL2组和HOXC10-siRNA-2+reCCL2组分别为287.00±3.61和280.67±2.31,<0.05)。HOXC10-siRNA-1组和HOXC10-siRNA-2组中M2型巨噬细胞相关基因TGF-β的表达水平分别为(0.30±0.02)和(0.28±0.02),低于NC组的(1.06±0.10)(<0.05)。HOXC10-siRNA-1组和HOXC10-siRNA-2组中M1相关基因NOS2的表达分别为(11 413.95±1 911.85)和(5 894.00±945.21),高于NC组的(13.39±4.32)(<0.05)。HOXC10在胶质瘤中高表达,与胶质瘤患者的不良预后呈正相关。敲低HOXC10可抑制人胶质瘤U251细胞的增殖、迁移和转移。HOXC10可能通过促进CCL2的表达以及募集和极化肿瘤相关巨噬细胞(M2巨噬细胞)在胶质瘤微环境中发挥免疫抑制作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验